Abstract
Mutant p53 could have either a dominant negative effect or a gain of function to interfere with p53’s ability to maintain genomic stability. In the present study, we screened for TP53 mutations in hepatocellular carcinoma (HCC) samples from 202 Chinese patients, followed by analysis of transcriptional and apoptotic activities of 21 p53 mutants with or without wild-type p53 present. We identified a new point mutation p.P72A, and a mutation (p.E294SfsX51) with a record long frameshift. We found TP53 mutations in HCC bear mutants without a dominant wild-type p53 inhibition on p21 transcription at a higher frequency. We found an anti-correlation for p53 WT/mutant heterotetramer to activate p21 and BAX transcription, i.e., at given p53 WT/mutant concentration, the fold increase p21 transcription is proportional to the fold of decreasing BAX transcription. Our kinetic model reproduced the trend in the experimental observation and confirmed that the p53 WT-dimer/mutant- heterotetramer is the major species to confer the differential activation of p21 and BAX transcription. p53 may have different binding modes on p21 and BAX, most likely resulting from the combinational effects of core domain binding and C-terminal mediation. Our study demonstrated that p53 mutants interfere with the ability of WT p53 to maintain genomic stability.
Keywords: TP53, mutation, hepatocellular carcinoma, genome stability, apoptosis.
Current Pharmaceutical Design
Title:Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy
Volume: 20 Issue: 8
Author(s): Xiaona Ji, Lijie Ma, Qiang Huang, Zijuan Li, Jing Zhao, Weixue Huang, Buyong Ma and Long Yu
Affiliation:
Keywords: TP53, mutation, hepatocellular carcinoma, genome stability, apoptosis.
Abstract: Mutant p53 could have either a dominant negative effect or a gain of function to interfere with p53’s ability to maintain genomic stability. In the present study, we screened for TP53 mutations in hepatocellular carcinoma (HCC) samples from 202 Chinese patients, followed by analysis of transcriptional and apoptotic activities of 21 p53 mutants with or without wild-type p53 present. We identified a new point mutation p.P72A, and a mutation (p.E294SfsX51) with a record long frameshift. We found TP53 mutations in HCC bear mutants without a dominant wild-type p53 inhibition on p21 transcription at a higher frequency. We found an anti-correlation for p53 WT/mutant heterotetramer to activate p21 and BAX transcription, i.e., at given p53 WT/mutant concentration, the fold increase p21 transcription is proportional to the fold of decreasing BAX transcription. Our kinetic model reproduced the trend in the experimental observation and confirmed that the p53 WT-dimer/mutant- heterotetramer is the major species to confer the differential activation of p21 and BAX transcription. p53 may have different binding modes on p21 and BAX, most likely resulting from the combinational effects of core domain binding and C-terminal mediation. Our study demonstrated that p53 mutants interfere with the ability of WT p53 to maintain genomic stability.
Export Options
About this article
Cite this article as:
Ji Xiaona, Ma Lijie, Huang Qiang, Li Zijuan, Zhao Jing, Huang Weixue, Ma Buyong and Yu Long, Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy, Current Pharmaceutical Design 2014; 20 (8) . https://dx.doi.org/10.2174/13816128113199990070
DOI https://dx.doi.org/10.2174/13816128113199990070 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Nanosystems: An Innovative Tools for Medicinal Chemistry)
Current Topics in Medicinal Chemistry Critical Role of IL-8 Targeting in Gliomas
Current Medicinal Chemistry Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
Current Cancer Drug Targets <i>Ralstonia Mannitolilytica</i>, an Unusual Pathogen in the Neonatal Intensive Care Unit: A Case of Neonatal Sepsis and Literature Review
Infectious Disorders - Drug Targets The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Target Recognition Molecules and Molecular Modeling Studies
Current Topics in Medicinal Chemistry Is Biotechnological Next-Generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?
Current Pharmaceutical Biotechnology Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Trials in Children
Reviews on Recent Clinical Trials Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Targeting Cancer using Curcumin Encapsulated Vesicular Drug Delivery Systems
Current Pharmaceutical Design Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Advances in Computational Structure-Based Drug Design and Application in Drug Discovery
Current Topics in Medicinal Chemistry Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer
Current Medicinal Chemistry Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry RecQ Family Helicases in Replication Fork Remodeling and Repair: Opening New Avenues towards the Identification of Potential Targets for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry